From Efficacy to Access in Long-Acting HIV Therapy

Over the past three decades, advances in antiretroviral therapy (ART) have dramatically improved life expectancy, decreased frailty, and improved quality of life for persons with human immunodeficiency virus (HIV). 1,2 These gains have accrued primarily among those who can reliably access health care and adhere to daily treatment. For many people who face structural and behavioral barriers to adherence, durable viral suppression remains elusive despite the availability of highly effective ART. Long-acting injectable ART offers the potential to extend the benefits of HIV treatment to populations in which adherence to daily oral ART has proved difficult. Although two phase 3 clinical trials . . .